Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
15 studies found for:    Open Studies | copd | United States, North Carolina
Show Display Options
Rank Status Study
1 Recruiting The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort
Conditions: Chronic Obstructive Pulmonary Disease (COPD);   Emphysema;   Chronic Bronchitis
Intervention:
2 Recruiting Imaging Regional Lung Defect Severity
Condition: COPD
Interventions: Drug: Perfluorinated Gas/Oxygen Mixture;   Other: High Resolution CT of the Chest
3 Recruiting Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease (SAD-COPD)
Conditions: COPD;   Anxiety;   Depression;   Stress
Interventions: Drug: Sertraline;   Drug: Placebo
4 Recruiting Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)
Condition: COPD
Interventions: Drug: BGF MDI 320/14.4/9.6 μg;   Drug: GFF MDI 14.4/9.6 μg;   Drug: BGF MDI 160/14.4/9.6 μg;   Drug: BFF MDI 320/9.6 μg
5 Recruiting Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Condition: COPD
Interventions: Drug: BGF MDI (PT010) 320/14.4/9.6 μg;   Drug: GFF MDI (PT003) 14.4/9.6 μg;   Drug: BFF MDI (PT009) 320/9.6 μg
6 Recruiting A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)
Condition: COPD
Interventions: Drug: BGF MDI 320/14.4/9.6 μg;   Drug: GFF MDI (PT003) 14.4/9.6 μg;   Drug: BFF MDI (PT009) 320/9.6 μg;   Drug: Symbicort® Turbuhaler® (TBH) Inhalation Powder
7 Recruiting Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
Condition: Chronic Obstructive Pulmonary Disorder
Interventions: Drug: BFF MDI 320/9.6 μg;   Drug: BFF MDI 160/9.6 μg;   Drug: FF MDI 9.6 μg;   Drug: BD MDI 320 μg;   Drug: Symbicort® TBH 400/12 μg BID
8 Recruiting A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)
Condition: Chronic Obstructive Pulmonary Disorder
Interventions: Drug: BFF MDI (PT009) 320/9.6 μg;   Drug: BFF MDI (PT009) 160/9.6 μg;   Drug: FF MDI (PT005) 9.6 μg
9 Recruiting A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
Condition: Chronic Obstructive Pulmonary Disease, COPD
Interventions: Drug: QBW251;   Drug: Placebo
10 Recruiting Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: GSP304 (tiotropium bromide) Inhalation Solution;   Drug: GSP304 Placebo Inhalation Solution;   Drug: Spiriva® Respimat® inhalation spray
11 Recruiting Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
Conditions: Asthma;   Chronic Obstructive Pulmonary Disease;   Interstitial Lung Disease;   Cystic Fibrosis;   Pulmonary Hypertension
Intervention: Drug: Xenon
12 Recruiting Observational Study of Obstructive Lung Disease (NOVELTY)
Conditions: Asthma;   COPD;   Chronic Obstructive Pulmonary Disease
Interventions: Procedure: Blood draw;   Procedure: Urine;   Procedure: Lung function measurements;   Procedure: Fractional Exhaled Nitric Oxide (FENO)
13 Recruiting Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)
Conditions: Pulmonary Disease, Chronic Obstructive;   Emphysema;   Bronchitis, Chronic
Intervention:
14 Not yet recruiting Losartan Effects on Emphysema Progression
Condition: Emphysema
Interventions: Drug: Losartan;   Drug: Placebo
15 Recruiting Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
Condition: Emphysema
Interventions: Device: Spiration Valve System;   Other: Medical Management

Study has passed its completion date and status has not been verified in more than two years.